DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Adalimumab
Adalimumab
BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
Old and New Challenges in Uveitis Associated with Behçet's Disease
Download
Infliximab, Adalimumab and Golimumab for Treating Moderately
Benlysta® (Belimumab)
Cimzia (Certolizumab Pegol) AHM
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Monoclonal Antibodies As Neurological Therapeutics
Tysabri® (Natalizumab)
Immunopharmacology: a Guide to Novel Therapeutic Tools - Francesco Roselli, Emilio Jirillo
Benlysta, INN- Belimumab
Certolizumab Pegol for Rheumatoid Arthritis: Effective in Combination with Methotrexate Or As Monotherapy
The Effect of Certolizumab Drug Concentration and Anti-Drug Antibodies on TNF Neutralisation L.C
Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities
Versus Arthritis Drug Information
INN Working Document 05.179 Update 2011
An Indirect Comparison of Infliximab Versus Adalimumab Or Golimumab for Active Ulcerative Colitis
Humira, INN-Adalimumab;
Top View
Golimumab: a New Anti-TNF Agent on the Horizon for Inflammatory Arthritis
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
Humira), Adalimumab-Atto (Amjevita
Adalimumab (Humira®) Is an Antibody Against a Pro-Inflammatory Protein (Cytokine) Called Tumor Necrosis Factor Α (Anti-TNF)
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
CIMZIA (Certolizumab Pegol) for Injection, for Subcutaneous Use CIMZIA (Certolizumab Pegol) Injection, for Subcutaneous Use ------CONTRAINDICATIONS------ Initial U.S
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Adalimumab Level with Reflex to Adalimumab Antibody
Successful Treatment of Hidradenitis Suppurativa in the Setting of Crohn Disease with Combination Adalimumab and Ustekinumab
CLINICAL PROTOCOL HGS1006-C1113 Protocol Amendment: 03 Eudract Number: 2011-005667-25 Date: 22 MAY 2017
Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
Comparative Efficacy Between Adalimumab and Infliximab in The
Biologic Therapy for Posterior Uveitis and Panuveitis by Sirichai Pasadhika, MD; Eric B
HUMIRA® (Adalimumab) Injection, for Subcutaneous Use • Administered by Subcutaneous Injection (2) Initial U.S
Crohn's Disease – Infliximab
Customs Tariff - Schedule Xxi - 1